FY2029 Earnings Estimate for CRBP Issued By HC Wainwright

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP - Free Report) - HC Wainwright issued their FY2029 earnings estimates for Corbus Pharmaceuticals in a report issued on Monday, February 10th. HC Wainwright analyst A. Maldonado anticipates that the biopharmaceutical company will post earnings per share of ($3.56) for the year. HC Wainwright currently has a "Buy" rating and a $75.00 price target on the stock. The consensus estimate for Corbus Pharmaceuticals' current full-year earnings is ($4.23) per share.

CRBP has been the subject of a number of other research reports. StockNews.com upgraded shares of Corbus Pharmaceuticals to a "sell" rating in a report on Monday, January 13th. Piper Sandler began coverage on shares of Corbus Pharmaceuticals in a report on Monday, December 2nd. They set an "overweight" rating and a $35.00 price objective for the company. Finally, Wedbush restated an "outperform" rating and set a $51.00 price objective on shares of Corbus Pharmaceuticals in a report on Monday, November 4th. One equities research analyst has rated the stock with a sell rating, eight have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, Corbus Pharmaceuticals currently has an average rating of "Moderate Buy" and an average price target of $61.38.

Corbus Pharmaceuticals Stock Down 10.2 %

NASDAQ CRBP traded down $0.97 during trading hours on Wednesday, reaching $8.51. 1,161,638 shares of the company were exchanged, compared to its average volume of 207,157. Corbus Pharmaceuticals has a 1 year low of $8.01 and a 1 year high of $61.90. The business's 50 day simple moving average is $12.07 and its 200-day simple moving average is $26.09. The stock has a market capitalization of $103.65 million, a P/E ratio of -1.81 and a beta of 2.63.

Hedge Funds Weigh In On Corbus Pharmaceuticals

Several hedge funds have recently bought and sold shares of the company. State Street Corp grew its stake in Corbus Pharmaceuticals by 34.6% during the third quarter. State Street Corp now owns 595,576 shares of the biopharmaceutical company's stock valued at $12,287,000 after acquiring an additional 153,243 shares in the last quarter. Altium Capital Management LLC grew its stake in Corbus Pharmaceuticals by 97.4% during the fourth quarter. Altium Capital Management LLC now owns 385,000 shares of the biopharmaceutical company's stock valued at $4,543,000 after acquiring an additional 190,000 shares in the last quarter. Geode Capital Management LLC grew its stake in Corbus Pharmaceuticals by 5.5% during the fourth quarter. Geode Capital Management LLC now owns 263,532 shares of the biopharmaceutical company's stock valued at $3,110,000 after acquiring an additional 13,773 shares in the last quarter. Renaissance Technologies LLC grew its stake in Corbus Pharmaceuticals by 769.4% during the fourth quarter. Renaissance Technologies LLC now owns 139,100 shares of the biopharmaceutical company's stock valued at $1,641,000 after acquiring an additional 123,100 shares in the last quarter. Finally, Northern Trust Corp grew its stake in Corbus Pharmaceuticals by 12.4% during the fourth quarter. Northern Trust Corp now owns 103,264 shares of the biopharmaceutical company's stock valued at $1,219,000 after acquiring an additional 11,400 shares in the last quarter. Hedge funds and other institutional investors own 64.64% of the company's stock.

About Corbus Pharmaceuticals

Corbus Pharmaceuticals Holdings, Inc, a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, a peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity.